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This study explores the manifestation and measurement of anxiety symptoms in 415 children with
ASDs on a 20-item, parent-rated, DSM-IV referenced anxiety scale. In both high and low-
functioning children (IQ above vs below 70), commonly endorsed items assessed restlessness,
tension and sleep difficulties. Items requiring verbal expression of worry by the child were rarely
endorsed. Higher anxiety was associated with functional language, IQ above 70 and higher scores
on several other behavioral measures. Four underlying factors emerged: Generalized Anxiety,
Separation Anxiety, Social Anxiety and Over-arousal. Our findings extend our understanding of
anxiety across IQ in ASD and provide guidance for improving anxiety outcome measurement.
Keywords
Autism Spectrum Disorders; anxiety; measurement; comorbidity
Autism spectrum disorders (ASDs), including Autistic Disorder, Asperger’s Disorder and
Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS), are characterized
by impairments in social reciprocity and communication, together with repetitive and
restricted behaviors and interests. In addition to these core symptoms, an estimated 40% of
children with ASDs fulfill diagnostic criteria for an anxiety disorder (van Steensel et al.
2011) and as many as 84% have impairing, subclinical anxiety symptoms (White et al.
2009). Co-occurring anxiety can cause acute distress, amplify the core symptoms of ASD
and trigger behavioral difficulties including tantrums, aggression and self-injury (Canitano
2006). Despite the prevalence of anxiety in ASDs, it remains unclear whether anxiety
difficulties constitute a separate condition or align more closely with core ASD features. For
example, social avoidance in Social Anxiety Disorder may appear similar to social
withdrawal in ASDs. Furthermore, the appearance of anxiety symptoms may differ in
children across the range of intellectual functioning and verbal abilities, presenting a key
challenge for anxiety measurement in this group.
In early descriptions of autism, Kanner (1943) observed children with an ‘anxiously
obsessive desire for the maintenance of sameness’. The third edition of the Diagnostic and
Statistical Manual (DSM-III; American Psychiatric Association 1980) integrated anxiety
symptoms within the core ASD criteria, including ‘intense and unusual anxieties’, ‘sudden,
excessive anxiety’ and ‘unexplained panic attacks’. In the DSM-IV (and the proposed
criteria of DSM-V) however, anxiety is not essential for an ASD diagnosis (American
Psychiatric Association 2000). The DSM-IV also advises that Separation Anxiety Disorder,
Social Anxiety Disorder and Generalized Anxiety Disorder can only be diagnosed if the
symptoms are not better accounted for by the ASD itself (Witwer and Lecavalier 2010). A
more thorough understanding of the nature of anxiety in ASDs would facilitate assessment
and detection of change with treatment.
The common co-occurrence of anxiety in ASDs has been confirmed in over forty studies to
date, using both dimensional (Lecavalier 2006; Kim et al. 2000) and categorical (Weisbrot et
al. 2005; Gadow et al. 2004, 2005) approaches to measurement. In a comprehensive review,
White and colleagues (White et al. 2009) reported that 11 to 84% of children with ASDs
exhibit impairing anxiety symptoms. This variation likely stems from differences in sample
Hallett et al. Page 3






















size and ascertainment, as well as the anxiety measure employed. A meta-analysis of 31
studies showed that the most common anxiety diagnoses were specific phobia (30%),
Obsessive Compulsive Disorder (OCD) (17%), social anxiety (17%) and generalized anxiety
(15%) (van Steensel et al. 2011). Children with ASDs were over twice as likely as typically
developing children to reach diagnostic cut-off for each anxiety disorder (Costello et al.
2005)..
The impact of cognitive ability requires particular attention when considering anxiety in
ASDs. Subjects in previous samples have differed in their intellectual functioning and many
reports have focused exclusively on children with ‘high-functioning’ autism or Asperger’s
Disorder (White et al. 2009). Three studies, with sample sizes ranging from 172 to 1202,
reported greater parent-rated anxiety symptoms in higher-functioning children with ASDs
compared to children with IQ below 70 (Sukhodolsky et al. 2008; Weisbrot et al. 2005;
Mazurek and Kanne 2010). In contrast, according to the meta-analysis by van Steensel and
colleagues (2011), anxiety disorders were more common in participants with lower IQ
scores across ASD subtypes. These inconsistent findings regarding anxiety and IQ may be
attributable to the challenges of assessing anxiety in lower-functioning children–resulting in
false positives or false negatives.
A previous study by Sukhodolsky and colleagues (2008) investigated anxiety symptoms in a
sample of 5–17 year-olds with ASDs (N=172). Their measure was the parent-reported 20-
item anxiety scale of the Child and Adolescent Symptom Inventory (Gadow and Sprafkin
1998, 2002), which showed good internal consistency across IQ. These investigators
examined the association between anxiety in ASD and behavioral difficulties and observed
low correlations between anxiety and measures of irritability, hyperactivity and adaptive
behavior. Finally, higher levels of anxiety were associated with functional language, higher
IQ and higher levels of stereotyped behaviors.
The current study represents a timely extension of the findings by Sukhodolsky et al (2008),
using the same CASI-Anxiety scale in a related but expanded sample (N=415). First, we
aimed to explore the frequency and distribution of anxiety symptoms in children with ASDs
and the relationship between anxiety and other measures of problem behavior and adaptive
functioning. We then aimed to broaden investigation to the item level, exploring the factor
analytic structure of the CASI-Anxiety and the applicability of items across IQ. Finally we
compared the clinical characteristics of children with the highest levels and lowest levels of
anxiety in this sample in order to profile children with the most severe anxiety difficulties.
Methods
Participants
445 participants (aged 4–17 years) took part in one of four federally-funded, multisite
treatment trials for ASDs (Research Units on Pediatric Psychopharmacology (RUPP)
Autism Network 2002, 2005; King et al. 2009; Aman et al. 2009; Scahill et al. 2012). The
studies were approved by each institutional review board and written informed consent was
obtained from parents or legal guardians prior to data collection. Developmentally able
minors also provided assent.
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Samples from two of these studies were included in a previous paper (Sukhodolsky et al.
2008). The first (RUPP 1, Research Units on Pediatric Psychopharmacology (RUPP) Autism
Network 2002) was a double-blind placebo-controlled trial of risperidone in children with
Autistic Disorder (N=101) and serious behavioral problems. RUPP 2 targeted hyperactivity
and compared methylphenidate versus placebo in children with ASDs (N=66) (Research
Units on Pediatric Psychopharmacology (RUPP) Autism Network 2005).
The current study included participants from two additional trials. RUPP 3 (Aman et al.
2009) compared risperidone only with risperidone and parent management training in 124
children with an ASD diagnosis and severe behavioral problems. The final study
randomized 149 children with ASDs to citalopram or placebo for moderate or greater
repetitive behaviors (King et al. 2009; Scahill et al. 2012).
CASI-Anxiety data were available for 415 children (353 boys, 62 girls). Children with
incomplete or missing data (N=30; 6.7%) were significantly younger (mean 7.0, sd 1.74
years versus 8.47, sd 2.87), had lower Vineland Communication scores (mean 43.34, sd
13.29 versus 57.16, sd 22.50) and lower ABC-Irritability scores (mean 16.90, sd 9.55 versus
21.39, sd 10.87) compared to the remaining sample.
The majority (n=336, 81%) of children were diagnosed with Autistic Disorder, 200 (51%)
had an IQ greater than or equal to 70, and 94 (23%) were classified as non-verbal. All
participants were healthy, medication-free for at least two weeks (one month for fluoxetine
or antipsychotic medications) prior to baseline and judged free of another psychiatric
condition in need of treatment. Based on parent-report, the sample was 70% Caucasian, 11%
African-American, 8% Hispanic, 7% Asian and 4% ‘other’.
Procedure
The current study uses datapretreatment assessment for each trial. incorporated tests of IQ
and adaptive behavior, along with medical and psychiatric histories, a physical examination
and parent-rated questionnaires. The diagnostic assessment was conducted by an
experienced team at each site and corroborated by the Autism Diagnostic Interview-Revised
(ADI-R, Le Couteur 2003). Diagnosis of Asperger’s Disorder or PDD-NOS was based on
DSM-IV criteria using all available clinical information.
Measures
Child and Adolescent Symptom Inventory (CASI)—This 132-item, parent-rated
scale is a reliable and valid screening instrument for DSM-IV psychiatric disorders (Gadow
and Sprafkin 1998, 2002; Sprafkin et al. 2002). Items are scored on a scale from 0 (never) to
3 (very often); with scores of 2 and 3 indicating clinical significance.
CASI-Anxiety scale—The CASI includes 26 items across several DSM-IV anxiety
disorders: generalized anxiety (8 items), separation anxiety (8 items), Post Traumatic Stress
Disorder (PTSD, 2 items), somatization (2 items), social phobia (2 items), OCD (2 items),
simple phobia (1 item) and panic disorder (1 item). The Symptom Severity score (the sum of
all CASI anxiety items) has demonstrated satisfactory internal consistency, reliability and
validity in typically developing, clinic-referred and ASD samples (Sprafkin et al. 2002).
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In a previous investigation, 6 items were excluded prior to analysis (Sukhodolsky et al.
2008). The two PTSD items were removed due to low occurrence in ASDs. Four items were
excluded to reduce overlap with oppositional defiant disorder (ODD), ADHD and OCD. For
these analyses, we included subjects with at least 18 of 20 items completed (the total score
was calculated using a mean scale replacement).
CASI-PDD scale—The current study also used the 12-item CASI-PDD scale, which
assesses social deficits, communication problems and repetitive and unusual behaviors.
The Aberrant Behavior Checklist (ABC)—This 58-item, parent-rated scale of
childhood behavior, assesses i) Irritability (aggression, tantrums, self-injury; 15 items; α in
this sample = 0.88); ii) Social Withdrawal / Lethargy (social interest, response to others; 16
items); iii) Stereotypic Behavior (7 items); iv) Hyperactivity (16 items) and v) Inappropriate
Speech (excessive talking, repeating phrases; 4 items) (Aman et al. 1985). Items are scored
from 0 (not a problem) to 3 (severe problem). The ABC has solid validity and reliability
from previous studies and has normative data in developmentally disabled populations
(Brown et al. 2002; Marshburn and Aman 1992).
Vineland Adaptive Behavior Scales—The Vineland is a reliable and valid semi-
structured parent interview designed to assess adaptive competencies in childhood (Sparrow
et al. 1984). The current analyses included three domains i) Communication ii) Daily living
iii) Socialization. Raw scores are converted to standard scores (mean 100; SD 15), with
higher scores representing greater adaptive functioning.
Children’s Yale-Brown Obsessive Compulsive Scale modified for Pervasive
Developmental Disorders (CYBOCS-PDD)—This is a 5-item, clinician-rated scale
adapted from the 10-item CYBOCS designed to quantify symptom severity in children with
OCD (Goodman et al. 1989; Scahill et al. 1997). Given the difficulty of assessing obsessions
in children with ASDs, the five obsession items of the original CYBOCS were dropped.
Thus, the CYBOCS-PDD retains the five compulsion items and uses the parent as the
primary informant. Several repetitive behaviors relevant to ASD were added to the symptom
checklist and the probes were adjusted to make them developmentally appropriate for
children with ASDs. The CYBOCS-PDD has demonstrated reliability, validity and
sensitivity to change (McDougle et al. 2005; Scahill et al. 2006).
Intellectual Functioning—Several IQ tests were used based on the participants’ age and
ability. These included the Wechsler Intelligence Scale for Children-III (Wechsler 1991), the
Wechsler Preschool and Primary Scale of Intelligence-Revised (Wechsler 1989), the Mullen
Scales of Early learning (Mullen 1995), the Leiter International Performance Scale-Revised
(Roid and Miller 1997) and the Slosson Intelligence Test (Jensen and Armstrong 1985). IQ
scores were available for 392 children (23 could not be tested). Given the range of
assessment employed, children were classified with IQ below 70 or IQ greater than or equal
to 70.
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We conducted descriptive analyses of the heterogeneous sample. The internal consistency of
the CASI-Anxiety scale was assessed with the Cronbach alpha statistic. The distributions of
CASI-Anxiety scores were examined for the full sample and for children with IQ above and
below 70. T-tests were used to explore differences in CASI-Anxiety scores according to
ethnicity, ASD diagnosis, IQ and age (above and below the median). A Pearson’s
correlation was also calculated between the CASI-Anxiety and age to further investigate th
relationship between age and anxiety.
Correlations (Pearson’s or Spearman’s Rank) were used to examine associations between
the CASI-Anxiety and the ABC subscales, the Vineland and the CYBOCS-PDD, for the full
sample and children with IQ above and below 70. Differences in these correlations were
assessed using Fisher’s r-to-z transformations.
Chi-square and t-tests were used to compare the highest and lowest quartile of CASI-
Anxiety scorers on IQ (above and below 70), the presence of language (verbal or non-
verbal) and clinical indices (ABC, CYBOCS-PDD, CASI-PDD and Vineland Adaptive
Behavior Scales). Logistic regression was used to test associations with membership of the
high anxiety group. First, individual categorical variables were assessed, such as: language
(verbal vs. nonverbal); ethnicity (Caucasian vs. all other ethnicities); diagnosis (Autistic
Disorder versus PDD-NOS/Asperger’s Disorder), age (above vs. below the median) and IQ
(above or below 70). Univariate analyses were also conducted using the upper quartile as a
cut off for each of the ABC, Vineland, CYBOCS-PDD and CASI-PDD scales. Variables
showing a significant association with high anxiety were included within a multivariate
forward logistic regression model, controlling for age and gender.
To evaluate scale items, we examined the per-item mean and the number of children scoring
at a clinically significant level (score of two (often) or three (very often)). T-tests were used
to compare the endorsement of items between children with an IQ above and below 70.
Exploratory factor analysis (EFA) was employed to identify factor loadings underlying the
items. Confirmatory factor analysis (CFA) compared the fit of different models to the
observed data. Acknowledging the potential drawbacks of using the same sample for CFA
and EFA, we conducted the EFA with the full sample and the CFA with half the sample
selected at random.
EFA was conducted with the Comprehensive Exploratory Factor Analysis (CEFA) software.
Ordinary least squares was selected as the discrepancy function because it requires fewer
assumptions than maximum likelihood estimation or generalized least squares estimation.
CASI items are scored on an ordinal scale. Therefore, we conducted factor analysis with
polychoric correlations matrices rather than Pearson correlations, which could have
underestimated inter-item associations.
CFA, using Lisrel,(Jöreskog and Sörbom 2004) compared the factor structure derived from
the EFA to a one-factor solution. Root Mean Square Error Approximation (RMSEA) and
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Root Mean Square Residuals (RMR) were used as fit statistics. Lower RMSEA and RMR
scores (ideally <0.05) indicate a better model fit.
Results
Sample Characteristics
The demographic and clinical characteristics of the study sample (N=415) are provided in
Table 1. The proportion of children with an IQ of 70 or greater in the RUPP 2 (49%), RUPP
3 (56%) and STAART studies (54%) was higher than RUPP 1 (19%) (χ2 (3) = 38.79;
p<0.01). ABC Irritability subscale scores differed between groups (F(3,106)=111.53, p<0.01),
being highest in RUPP 3 (mean 29.48 sd 6.62) and lowest in the STAART study (mean
12.19, sd 8.67). ABC Hyperactivity subscale scores were also highest for RUPP 3 (mean
35.64, sd 8.40) and lowest for the STAART study (mean 19.90, sd 11.67) (F(3,408)=64.28,
p<0.01). Mean CASI-Anxiety scores differed between groups (F(3,411)=3.09, p<0.01), being
highest in RUPP 3 (16.19, sd 10.05) and lowest in the STAART study (12.84, sd 9.27).
Although there are some differences in the characteristics of the four samples, these
variations increase the heterogeneity of the combined dataset and fit with the exploratory
nature of this study..
CASI-Anxiety scores ranged from 0 to 50 (mean 14.17, sd 9.4) and were slightly positively
skewed (skew 1.03, kurtosis 0.94). The internal consistency of the items was high (α=0.87).
Figure 1 shows the distribution of scores in children with IQ above and below 70. Children
with an IQ of 70 or above were significantly more anxious (mean 16.47, sd 10.26) than
those with IQ below 70 (mean 12.24, sd 7.94) (t(390)=4.58, p<0.01). Nonverbal children
with IQ below 70 had even lower scores (mean 10.33, sd 6.73). When adjusting for IQ, there
were no significant differences in anxiety across ASD diagnoses (F(2,388)=2.47; p=0.08).
There were no significant differences in anxiety between younger and older (below and
above median age) children (t(415)=1.13; p=0.26), between Caucasian children and children
of other ethnicities (t(415)=1.25; p=0.24), or between males and females (t(415)=1.24;
p=0.22).
Pearson correlations (or Spearman for ABC Inappropriate Speech subscale and the
CYBOCS-PDD scales, which were not normally distributed) between the CASI-Anxiety and
behavioral scales are shown in Table 2. In the sample as a whole, correlations were often
significant - but small to medium. There were slightly higher correlations between the
CASI-Anxiety and these behavioral scales in children with an IQ below 70 compared to
those with an IQ of 70 or above, although this difference only reached significance (p<0.05)
for the ABC Inappropriate Speech subscale (z=2.3; p=0.02). The pattern of mean
comparisons and correlations was unchanged when performed with transformed CASI-
Anxiety scores to correct for the slightly positive skew.
Children with high levels of anxiety
Children in the upper and lower quartile on the CASI-Anxiety scale were comparable in age
(t (217)=0.56, p=0.58). A greater proportion of children with high anxiety had IQ scores of
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70 or above (63%) compared to the low anxiety group (36%) (χ2 (1)=14.28, p=0.01) and a
larger proportion were verbal (high anxiety: 90%; low anxiety: 64%; χ2 (1)= 19.74, p<0.01).
Table 3 shows that children in the high anxiety group scored significantly higher than
children in the low anxiety group for all the ABC subscales (p<0.05). Consistent with the
greater percentage of children with IQ of 70 or above, Vineland scales were also higher in
the high anxiety group (p<0.05). CASI-PDD scores were also significantly higher in the
high anxiety compared to the low anxiety group, suggesting greater ASD severity (p<0.01),
but there no group difference on the CYBOCS-PDD scale (p=0.18).
Univariate logistic regressions revealed six significant associations with membership of the
highest quartile on the CASI Anxiety scale: IQ of 70 or above (p<0.01), diagnosis of PDD-
NOS or Asperger’s Disorder (versus Autistic Disorder) (p=0.02), being verbal (p<0.01) and
scoring in the top quartile on the ABC Irritability, Social Withdrawal, Hyperactivity or
Inappropriate Speech subscales (p<0.01). These variables were then included within a
forward multivariate logistic regression, controlling for age and gender. The model provided
a good fit to the data according to the Hosmer and Lemeshow test (χ2=2.53, df=7, p=0.93).
Membership in the high anxiety group was most strongly associated with verbal ability (OR:
3.96 CI 1.37–11.41; p<0.01) and top quartile scores on the ABC Irritability (OR: 3.56 CI
1.37–9.25; p<0.01), Inappropriate Speech (OR: OR 4.19 CI 1.79–9.80; p<0.01) and
Hyperactivity (OR: 2.52 CI 1.04–6.10; p<0.01) subscales. Children with IQ of 70 or above
were nearly three times as likely to be in the high anxiety group compared to intellectually
disabled children (OR: 2.92 CI 1.35–6.30; p<0.01).
Item-endorsement
Table 4 presents per-item means and the percentages of subjects scoring at the clinically
significant level (rating of 2 or 3) for children with IQ 70 or above 0 (N=192) and those
below 70 (N=200). Across the full sample, the three most commonly endorsed items were: i)
‘acts restless or edgy’ ii) ‘has difficulty falling asleep’ iii) ‘is more anxious in social
situations than other children’. The three least endorsed items were: i) ‘worries about
physical health’ ii) ‘has nightmares about being separated from parents’ iii) ‘complains
about feeling sick when separation is expected.’
Children with IQ above 70 showed significantly higher per-item means (p<0.05) than
children with IQ below 70 for 12 of the 20 items. The item ‘has difficulty controlling
worries’ showed the greatest disparity in per-item means across the low IQ (0.46) and high
IQ (1.16) groups. This difference in per-item mean score was even greater when compared
to the subgroup of non-verbal children in the low IQ group (N=92).
Factor Analysis
Factor solutions with two, three, four and five factors were considered. Of these, the four
factor solution was chosen for empirical reasons (e.g. high average factor loadings) and ease
of interpretation. Table 5 presents the loadings of each item on all four factors, which
corresponded with i) Generalized Anxiety ii) Separation Anxiety iii) Over-arousal
(restlessness, tension, sleep difficulties) and iv) Social Anxiety. Correlations between these
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factors were modest, ranging from 0.12 (between Separation Anxiety and Social Anxiety)
and 0.44 (between Generalized Anxiety and Separation Anxiety) (see Table 5). Items tended
to load strongly on one factor, with relatively weak loadings on the other three factors. The
one fear-rated item (‘is overly fearful of specific objects’), loaded moderately (0.41) onto the
Separation Anxiety factor. The five factor solution divided Separation Anxiety into two
factors and was discarded. The three factor solution, in contrast, did not distinguish between
social anxiety and over-arousal, perhaps due to the low number of social anxiety items.
Using half of the full sample selected at random, CFA showed that the four factor solution
fit the data significantly better (RMSEA = 0.04 90% CI: 0.02–0.05; RMR =0.08) than the
one factor solution (RMSEA = 0.12 90% CI: 0.105–0.124; RMR=0.13) (EFA and CFA
solutions are available on request).
Discussion
The current study examined anxiety symptoms in a large well-characterized sample of
subjects with ASDs using the 20-item CASI-Anxiety scale. The study replicates and extends
a previous study by Sukhodolsky and colleagues (2008), which used the same measure in a
related (although smaller) sample. The relatively large and heterogenous sample permitted
us to examine the anxiety rating at the item level, to explore the factor structure of the CASI-
Anxiety and the endorsement of individual items across IQ. To our knowledge, this is the
first study to examine the profile of youth with ASDs and high levels of anxiety on a
dimensional measure.
The distribution and psychometric properties of the CASI-Anxiety scale in this sample were
consistent with those of Sukhodolsky and colleagues (2008). The mean CASI anxiety score
for intellectually disabled children was significantly lower compared to those with an IQ of
70 or above. Nonetheless, both IQ groups showed an approximately normal distribution of
CASI Anxiety scores. The high internal consistency of the CASI-Anxiety items suggests
that these items are measuring a similar construct. Furthermore, the low correlations
between the CASI-Anxiety and the other behavioral scales suggest that this DSM-IV-based
anxiety symptom list is measuring something distinct from hyperactivity, irritability,
repetitive behavior, or adaptive functioning. The association with parent-rated ASD
symptoms was also modest, suggesting that anxiety symptoms do not align closely with
manifestations of ASD as measured on the CASI PDD scale. Compared to the children in
the lowest quartile on the CASI Anxiety scale, however, those in the highest quartile showed
a higher mean score on the CASI-PDD scale. Reports of increased ASD-like traits in
typically-developing children with anxiety disorders suggest a possible bidirectional
association of anxiety disorders and ASDs (Pine et al. 2008; Ivarsson and Melin 2008). This
association seems especially relevant to social anxiety disorder and ASD. However, the
current 20-item CASI Anxiety scale includes only 2 items of social anxiety. Given the
limited coverage of social anxiety, fuller exploration of the social impairments and social
anxiety in children with ASD awaits further study.
We observed that high scores on the CASI-Anxiety scale were associated with being verbal,
having an IQ of 70 or above and showing high levels of inappropriate speech, irritability and
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hyperactivity. Children with the highest levels of anxiety also had higher parent-rated ASD
severity scores than those who were less anxious. These associations could reflect the
overall behavioral disturbance of children in this sample or suggest that anxiety may amplify
other behavioral problems. It may also indicate that a combination of higher IQ, coupled
with a more severe behavioral impairment poses a greater risk for anxiety difficulties. This
is particularly interesting as irritability, ASD severity and hyperactivity are often associated
with lower IQ rather than higher IQ – a paradox that warrants further investigation. The
observation that children in the upper quartile on the CASI Anxiety scale had higher
Vineland scores is consistent with previous findings showing positive associations between
IQ and anxiety in ASDs (Gadow et al. 2005; Sukhodolsky et al. 2008; Weisbrot et al. 2005).
Children with higher IQ (particularly coupled with high ASD severity) may have greater
awareness of their social differences, but may remain unable to compensate effectively for
their difficulties. Given the limited coverage of social anxiety on the current 20-item CASI,
however, fuller exploration of the social impairments and social anxiety in children with
ASD awaits further study.
Considering the individual items of the CASI-Anxiety, the most and least endorsed
statements were the same in the high and low IQ groups. Items such as: ‘acts restless or
edgy’, ‘has difficulty falling asleep’ and ‘is extremely tense and unable to relax’ are directly
observable and were most commonly endorsed by parents. This result is consistent with
previous findings (Witwer and Lecavalier 2010). Some aspects of social anxiety (e.g. ‘is
more anxious in social situations than most children’) and separation anxiety (e.g. ‘is easily
upset when separation is expected’) were also highly endorsed across IQ groups.
Items such as ‘worries about physical health’, ‘has nightmares about being separated from
parents’ and ‘complains about feeling sick when separation is expected’ require inference by
the parent or direct expression by the child. Given the difficulties that children with ASDs
often have with communication, it is not surprising that these items were rarely endorsed at
the clinical level (a score of 2 or 3) (by 3.6% and 4.3% of the full sample respectively).
Other items relying on language (e.g. ‘complains about heart pounding’ and ‘worries that
disaster will cause separation from parents’) were rarely endorsed by parents of children
with intellectual disability. This observation is consistent with a previous study showing that
intellectually disabled children with ASDs are less likely to express excessive worry
(Witwer and Lecavalier 2010). The high language demand for items starting with ‘worries’
or ‘complains’ apparently limited the rate of endorsement in the lower IQ group, which, in
turn, contributed to the lower CASI Anxiety mean score for the intellectually disabled
group. Nonetheless, subjects with IQ of 70 or greater had significantly higher mean scores
than the intellectually disabled group on the 10 scale items with low verbal demand. This
suggests that, even when considering the more observable aspects of anxiety, higher
functioning children were rated as exhibiting more anxiety than children with lower IQ.”
The factor structure in this sample suggests that anxiety may be multifactorial in children
with ASDs. Although three factors corresponded to DSM-IV categories (Generalized
Anxiety, Separation Anxiety and Social Anxiety), the fourth factor was less anxiety specific,
encompassing ‘over-arousal’ symptoms such as restlessness and sleep difficulties. This
factor analysis relied on a predetermined set of DSM-derived items. These current items are
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weighted toward separation anxiety (8 of 20 items) with inadequate coverage of social
anxiety (2 of 20 items). Future adjustments may involve removal of rarely endorsed items
(e.g. the 3 items endorsed by less than 5% of this sample) and addition of items capturing
ASD-specific aspects of anxiety and emotional reactivity. Qualitative inquiry with parents
may contribute to improved understanding on the manifestations of anxiety in children with
ASDs across the IQ range.
There are several limitations of this study. First, this was a convenient sample of pediatric
participants in clinical trials selected for specific behavioral difficulties. Therefore, although
this was a relatively large and broad sample, the findings may not apply to the wider ASD
population. Our findings on divergent validity suggest that the CASI-Anxiety scale is
measuring a unique construct. However, we did not have another measure of anxiety (either
from parents or additional informants) and consequently we do not have evidence of
convergent validity. The small proportion of girls (15%) in the sample also hindered
comparisons by gender.
In conclusion, our findings contribute to a growing literature regarding the manifestation and
measurement of anxiety in children with ASDs. We observed that anxiety occurs across the
full range of IQ. Children with an IQ below 70 have lower scores, in part because the items
that rely on language are rarely endorsed and do not contribute to the total score. However,
our findings suggest that the CASI-Anxiety scale represents a promising starting point for
quantifying anxiety symptoms in this population. Further investigation is needed to
determine whether an adapted version of this scale may be useful as an outcome measure for
clinical trials.
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Frequency distributions of CASI-Anxiety scores for children with IQ i) below 70 ii) 70 or
above
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